536 related articles for article (PubMed ID: 9066111)
1. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
4. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
7. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
Thomson KS; Weber DA; Sanders CC; Sanders WE
Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
[TBL] [Abstract][Full Text] [Related]
8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
9. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Traub WH; Leonhard B
Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
12. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
13. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
London N; Thomson CJ; Amyes SG; Stobberingh E
FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
[TBL] [Abstract][Full Text] [Related]
14. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
[TBL] [Abstract][Full Text] [Related]
15. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Fass RJ; Prior RB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
19. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
20. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
